Variant Annotations
PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.
Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.
There are 3 annotations for this variant. Register or sign in to see them.
Connected Drugs
| Evidence | Drug |
|---|---|
| bupropion | |
| cyclophosphamide | |
| doxorubicin | |
| efavirenz |
Publications related to rs12721655 at chr19:41510282: 2
| Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. The Journal of pharmacology and experimental therapeutics. 2011. Zhang Haoming, et al. [Article:21659470@PubMed] | |
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. [Article:20179710@PubMed] |
Cross-References
- UCSC Golden Path:
- chr19:41510282
- dbSNP:
- rs12721655
Platform Availability
- Illumina